Download PDF
Klin Monbl Augenheilkd 2019; 236(04): 487-491
DOI: 10.1055/a-0828-7395
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Diagnostische Strategie und therapeutisches Dilemma bei akuter posteriorer und Panuveitis

Diagnostic Strategy and Therapeutic Dilemma in Acute Posterior and Panuveitis
Justus G. Garweg
1   Klinik für Uveitis, Berner Augenklinik am Lindenhofspital, Universität Bern, Schweiz
,
Juerg Messerli
2   Augenklinik, Universitätsspital Basel, Schweiz
› Author Affiliations
Further Information

Publication History

eingereicht 11 October 2018

akzeptiert 25 December 2018

Publication Date:
14 February 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die breite Differenzialdiagnose der akuten posterioren und Panuveitis, die meist jüngere Individuen und in mehr als der Hälfte beide Augen betrifft, macht die rasche diagnostische Einordnung und die therapeutische Entscheidung wegen ihrer erheblichen Konsequenzen für den weiteren Verlauf zu kritischen Schritten. Das Risiko eines bleibenden Visusverlustes infolge eines verzögerten Therapiebeginns ist dabei ebenso bedeutsam wie das Einleiten einer nicht genügend wirksamen Therapie. Klinische Präsentation (anatomische Lokalisation und Entzündungstyp), Verlauf und sekundär das Ansprechen auf die Akuttherapie lassen eine erste diagnostische Eingrenzung zu, wobei eine infektiöse Ätiologie in bis zu einem Drittel der Fälle vorliegt. Die häufigste akute posteriore Uveitis bei immunkompetenten Patienten ist eine akute virale Netzhautnekrose. Diese lässt sich oft klinisch nicht sicher von einer Behçet-Uveitis unterscheiden, solange keine systemischen Manifestationen vorliegen. Bis zur definitiven diagnostischen Einordnung muss deshalb bei makulabedrohender Erkrankung spätestens 24 Stunden nach Beginn einer antiviralen und antiparasitären Akuttherapie eine hochdosierte Steroidtherapie begonnen werden. Den therapeutischen Konsequenzen der Fehleinschätzung der Erkrankung stehen prognostische Überlegungen gegenüber, die ein aggressives Vorgehen gerade bei akuten posterioren Uveitiden rechtfertigen: Jede Verzögerung des Therapiebeginns vermehrt die infektiöse und entzündliche Gewebsschädigung, erhöht das Risiko einer Affektion des Partnerauges und anderer Organe, wohingegen der Einsatz höherer Steroiddosen, Immunsuppressiva und Biologika zu unkontrollierter Erregerproliferation und zu Rezidiven führen kann.

Abstract

Acute posterior and panuveitis mostly affect younger patients and affect both eyes in more than half of cases. Because of the severe consequences in the clinical course, rapid and broad differential diagnosis are critical steps. Permanent loss of vision after a delay in starting therapy and the initiation of ineffective treatment are both serious risks. The initial diagnostic classification is based on clinical presentation (anatomical localisation and type of inflammation) and clinical course and, secondarily, on the response to acute therapy. The aetiology is acute in as many as one third of cases. The most frequent acute posterior uveitis in immunocompetent persons is acute viral retinal necrosis. It is difficult to distinguish this clinically from Behçet uveitis, as long as there are no systemic manifestations. In patients with disease threatening the macula, high dose steroid therapy must be started no later than 24 hours after the start of antiviral and anti-parasitic acute therapy. Thus, misdiagnosis has therapeutic consequences. Moreover, the prognosis is favourably affected by aggressive treatment of acute posterior uveitis. Any delay in starting therapy increases infectious and inflammatory tissue damage, and increases the risk of involvement of the other eye and of other organs. On the other hand, the use of high doses of steroids, immunosuppressives and biological agents can lead to uncontrolled proliferation of the pathogen and relapses.

Schlüsselwörter

posteriore Uveitis - Panuveitis - infektiös - nicht infektiös - Differenzialdiagnose - Visusbedrohung

Key words

posterior uveitis - panuveitis - infectious diseases - non-infectious - differential diagnosis - vision at risk
 

  • Literatur

  • 1 Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005; 45: 1-13
    PubMedGoogle Scholar
  • 2 You C, Sahawneh HF, Ma L. et al. A review and update on orphan drugs for the treatment of noninfectious uveitis. Clin Ophthalmol 2017; 11: 257-265
    CrossrefPubMedGoogle Scholar
  • 3 Al-Dhibi HA, Al-Mahmood AM, Arevalo JF. A systematic approach to emergencies in uveitis. Middle East Afr J Ophthalmol 2014; 21: 251-258
    CrossrefPubMedGoogle Scholar
  • 4 Lee JH, Agarwal A, Mahendradas P. et al. Viral posterior uveitis. Surv Ophthalmol 2017; 62: 404-445
    CrossrefPubMedGoogle Scholar
  • 5 Deschenes J, Murray PI, Rao NA. et al. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16: 1-2
    CrossrefPubMedGoogle Scholar
  • 6 Tsirouki T, Dastiridou A, Symeonidis C. et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 2018; 26: 2-16
    CrossrefPubMedGoogle Scholar
  • 7 Barisani-Asenbauer T, Maca SM, Mejdoubi L. et al. Uveitis – a rare disease often associated with systemic diseases and infections – a systematic review of 2619 patients. Orphanet J Rare Dis 2012; 7: 57
    CrossrefPubMedGoogle Scholar
  • 8 Tran VT, Auer C, Guex-Crosier Y. et al. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm 1994; 2: 169-176
    CrossrefPubMedGoogle Scholar
  • 9 Guex-Crosier Y. [Epidemiology of uveitis]. Rev Prat 1999; 49: 1989-1994
    PubMedGoogle Scholar
  • 10 Lee JH, Mi H, Lim R. et al. Ocular Autoimmune Systemic Inflammatory Infectious Study – Report 3: Posterior and Panuveitis. Ocul Immunol Inflamm 2017; DOI: 10.1080/09273948.2017.1358377.
    CrossrefPubMedGoogle Scholar
  • 11 Nazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. Surv Ophthalmol 2013; 58: 203-232
    CrossrefPubMedGoogle Scholar
  • 12 Chen EJ, Bin Ismail MA, Mi H. et al. Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) – Report 1: epidemiology and classification. Ocul Immunol Inflamm 2018; 26: 732-746
    CrossrefPubMedGoogle Scholar
  • 13 Adán-Civera AM, Benítez-Del-Castillo JM, Blanco-Alonso R. et al. Burden and direct costs of non infectious uveitis in Spain. Reumatol Clin 2016; 12: 196-200
    CrossrefPubMedGoogle Scholar
  • 14 Reznicek L, Seidensticker F, Stumpf C. et al. Systematic analysis of wide-field fundus autofluorescence (FAF) imaging in posterior uveitis. Curr Eye Res 2014; 39: 164-171
    CrossrefPubMedGoogle Scholar
  • 15 Alberdi-Saugstrup M, Enevold C, Zak M. et al. Non-HLA gene polymorphisms in juvenile idiopathic arthritis: associations with disease outcome. Scand J Rheumatol 2017; 46: 369-373
    CrossrefPubMedGoogle Scholar
  • 16 Márquez A, Cordero-Coma M, Martín-Villa JM. et al. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. J Med Genet 2017; 54: 38-46
    CrossrefPubMedGoogle Scholar
  • 17 Huang XF, Lin D, Lin KH. et al. Genotype-phenotype association study reveals CFI-Rs13104777 to be a protective genetic marker against acute anterior uveitis. Ocul Immunol Inflamm 2018; 26: 51-56
    CrossrefPubMedGoogle Scholar
  • 18 Davoudi S, Navarro-Gomez D, Shen L. et al. NOD2 genetic variants and sarcoidosis-associated uveitis. Am J Ophthalmol Case Rep 2016; 3: 39-42
    PubMedGoogle Scholar
  • 19 Hsu YR, Huang JC, Tao Y. et al. Noninfectious uveitis in the Asia-Pacific region. Eye (Lond) 2019; 33: 66-77 doi:10.1038/s41433-018-0223-z
    CrossrefPubMedGoogle Scholar
  • 20 Verhagen FH, Bekker CPJ, Rossato M. et al. A disease-associated microRNA cluster links inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis. Invest Ophthalmol Vis Sci 2018; 59: 878-888
    CrossrefPubMedGoogle Scholar
  • 21 Wen X, Hu X, Miao L. et al. Epigenetics, microbiota, and intraocular inflammation: new paradigms of immune regulation in the eye. Prog Retin Eye Res 2018; 64: 84-95
    CrossrefPubMedGoogle Scholar
  • 22 Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006; 90: 103-108
    CrossrefPubMedGoogle Scholar
  • 23 Guymer R, Robman L. Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association?. Clin Exp Ophthalmol 2007; 35: 89-93
    CrossrefPubMedGoogle Scholar
  • 24 Drancourt M, Bodaghi B, Lepidi H. et al. Intraocular detection of Bartonella henselae in a patient with HLA-B27 uveitis. J Clin Microbiol 2004; 42: 1822-1825
    CrossrefPubMedGoogle Scholar
  • 25 Drancourt M, Berger P, Terrada C. et al. High prevalence of fastidious bacteria in 1520 cases of uveitis of unknown etiology. Medicine (Baltimore) 2008; 87: 167-176
    PubMedGoogle Scholar
  • 26 Fukushima H, Numaga J, Yoshimoto M. et al. An ocular cat-scratch disease patient positive for cytoplasmic anti-neutrophil cytoplasmic antibody. Graefes Arch Clin Exp Ophthalmol 2001; 239: 882-885
    CrossrefPubMedGoogle Scholar
  • 27 Habot-Wilner Z, Trivizki O, Goldstein M. et al. Cat-scratch disease: ocular manifestations and treatment outcome. Acta Ophthalmol 2018; 96: e524-e532
    CrossrefPubMedGoogle Scholar
  • 28 Sahlberg AS, Granfors K, Penttinen MA. HLA-B27 and host-pathogen interaction. Adv Exp Med Biol 2009; 649: 235-244
    PubMedGoogle Scholar
  • 29 Kaneko F, Togashi A, Saito S. et al. Behçetʼs disease (Adamantiades-Behçetʼs disease). Clin Dev Immunol 2011; 2011: 681956 doi:10.1155/2011/681956
    CrossrefPubMedGoogle Scholar
  • 30 Lin P. The role of the intestinal microbiome in ocular inflammatory disease. Curr Opin Ophthalmol 2018; 29: 261-266
    CrossrefPubMedGoogle Scholar
  • 31 Lee JH, Agarwal A, Mahendradas P. et al. Viral posterior uveitis. Surv Ophthalmol 2017; 62: 404-445
    CrossrefPubMedGoogle Scholar
  • 32 Akinsoji E, Goldhardt R, Galor A. A glimpse into uveitis in the aging eye: pathophysiology, clinical presentation and treatment considerations. Drugs Aging 2018; 35: 399-408
    CrossrefPubMedGoogle Scholar
  • 33 Pleyer U, Pohlmann D, Stübiger N. [Treatment of posterior non-infectious uveitis: current situation and future developments]. Ophthalmologe 2016; 113: 380-390
    CrossrefPubMedGoogle Scholar
  • 34 Abaño JM, Galvante PR, Siopongco P. et al. Review of epidemiology of uveitis in Asia: pattern of uveitis in a tertiary hospital in the Philippines. Ocul Immunol Inflamm 2017; 25 (Suppl. 01) S75-S80
    CrossrefPubMedGoogle Scholar
  • 35 Garweg JG, Tappeiner C. Zur Differentialdiagnose der infektiösen posterioren Uveitis. Klin Monatsbl Augenheilkd 2011; 228: 268-272
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Pleyer U, Chee SP. Current aspects on the management of viral uveitis in immunocompetent individuals. Clin Ophthalmol 2015; 9: 1017-1028
    PubMedGoogle Scholar
  • 37 de Parisot A, Kodjikian L, Errera MH. et al. Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). Am J Ophthalmol 2017; 178: 176-185
    CrossrefPubMedGoogle Scholar
  • 38 Patel AK, Newcomb CW, Liesegang TL. et al. Risk of retinal neovascularization in cases of uveitis. Ophthalmology 2016; 123: 646-654
    CrossrefPubMedGoogle Scholar
  • 39 Dick AD, Rosenbaum JT, Al-Dhibi HA. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology 2018; 125: 757-773
    CrossrefPubMedGoogle Scholar
  • 40 Davis JL. Diagnostic dilemmas in retinitis and endophthalmitis. Eye (Lond) 2012; 26: 194-201
    CrossrefPubMedGoogle Scholar
  • 41 Tajunisah I, Reddy SC, Tan LH. Acute retinal necrosis by cytomegalovirus in an immunocompetent adult: case report and review of the literature. Int Ophthalmol 2009; 29: 85-90
    CrossrefPubMedGoogle Scholar